Lutetium-177 Dotatate is an FDA-approved radiopharmaceutical for treating somatostatin receptor-positive neuroendocrine tumors. It delivers targeted radiation to cancer cells.
In the literature, Lutetium-177 Dotatate appears most often in work focused on cancer research. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.
Lutetium-177 Dotatate is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.
Tap a topic to see which peptides are most studied for it.
Abarelix is a synthetic GnRH antagonist that was approved for treating advanced prostate cancer. It was studied for its ability to suppress hormone production to manage certain cancers.
Buserelin is a synthetic GnRH agonist analog used clinically for hormone-sensitive conditions. Researchers study its effects on hormone regulation for conditions like prostate cancer, endometriosis, and fertility treatments.
G-CSF is a hematopoietic growth factor that stimulates the bone marrow to produce neutrophils. It is widely used in oncology to prevent and treat chemotherapy-induced low white blood cell counts.
Research use only. This page summarizes areas of published study and is not medical advice. No dosing, protocol, or usage guidance is provided.